Meta AnalysisID 356
云芝用于结直肠癌治疗 [Cochrane方案]
CRD42016045477
To assess the effects of Coriolus versicolor and its extracts on adverse effects during cancer treatment (chemotherapy and radiotherapy). To assess effects due to Coriolus versicolor and its extracts on survival, recurre
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Herb: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 356
- Evidence Id
- 8914
- Core Evidence Id
- 8914
- Source Meta Analysis Id
- 335
- Herb2 Meta Analysis Id
- HBMA000335
- Crd Id
- CRD42016045477
- Title
- Coriolus versicolor mushroom for colorectal cancer treatment [Cochrane Protocol]
- Review Question
- To assess the effects of Coriolus versicolor and its extracts on adverse effects during cancer treatment (chemotherapy and radiotherapy). To assess effects due to Coriolus versicolor and its extracts on survival, recurrence, and disease progression. To evaluate the evidence in relation to the type of preparation of the mushroom (e.g. whole fresh, dried, or extract).
- Study Type Included
- We will consider randomised controlled trials (RCTs) investigating the efficacy and safety of Coriolus versicolor and its extracts in participants with a confirmed diagnosis of colorectal cancer, in addition to conventional treatment. We will include trials regardless of language and publication status. We will consider all types of RCT design for inclusion, e.g. parallel-group and cluster-RCTs. We will only include trials including different types of cancer if data for colorectal cancer patients are reported separately.
- Condition Being Studied
- The Cochrane Colorectal Cancer Group
- Participant
- Adult patients (minimum age 18 years) diagnosed with colorectal cancer regardless of tumour stage, age, or gender. Diagnosis must be confirmed by biopsy and will be stratified by tumour site and stage.
- Animal
- Human Disease Modelled
- Intervention
- Interventions will include any preparation of Coriolus versicolor (raw plant, decoction, capsule, tablet, tincture, extract, injection), any part of the mushroom (mycelium, stem, root, leave, spore, or whole), at any dose and regimen. Trials will be included that compare: conventional treatment (chemotherapy with or without radiotherapy) plus Coriolus versicolor extract versus conventional treatment alone; conventional treatment and a complementary therapy plus Coriolus versicolor extract versus the same treatment without the extract; conventional treatment plus Coriolus versicolor extract versus conventional treatment plus placebo.</ul>
- Comparator Control
- Trials will be included that compare: conventional treatment (chemotherapy with or without radiotherapy) plus Coriolus versicolor extract versus conventional treatment alone; conventional treatment and a complementary therapy plus Coriolus versicolor extract versus the same treatment without the extract; conventional treatment plus Coriolus versicolor extract versus conventional treatment plus placebo.</ul>
- Main Outcome
- Overall survival at one year, three years, and five years. Adverse effect rates: the incidence of all reported adverse effects or toxicities, including modification of treatment or withdrawal from the trial due to adverse effects. </ul>
- Outcome Measure
- Additional Outcome
- Disease progression at one year (plus three years and five years, if data are available) confirmed radiologically or biopsy proven. Disease recurrence at one year (plus three years and five years, if data are available) confirmed radiologically or biopsy proven. Response rates based on recommended criteria (World Health Organization (WHO) criteria or RECIST - Response Evaluation Criteria in Solid Tumors) for solid tumours (Therasse 2000). Quality of life evaluated using any validated assessment tool. </ul>
- Study Method
- Intervention, Systematic review
- Keyword
- Agaricales; Colorectal Neoplasms; Humans; Treatment Outcome
- Contact
- Karen Pilkington [email protected]
- Organisational Affiliation
- The Cochrane Collaboration http://www.cochrane.org/
- Funding Source
- None specified
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- England, Scotland, China, Japan
- Review Stage
- Review Ongoing
- First Submission Date
- Registration Date
- 2016-08-08
- Anticipated Start Date
- 2016-01-15
- Anticipated Completion Date
- 2016-12-01
- Title Cn
- 云芝用于结直肠癌治疗 [Cochrane方案]
- Title En
- Coriolus versicolor mushroom for colorectal cancer treatment [Cochrane Protocol]
- Bilingual Status
- complete